Dendritic cell vaccine (DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial.

Lukas Rob,David Cibula,Paweł Knapp,Peter Mallmann,J. Klát,Lubos Minar,Pavel Bartoš,Josef Chovanec,Petr Valha,Marek Pluta,Zdeněk Novotný,Jiří Špaček,Bohuslav Melichar,Dariusz Kieszko,Jitka Fucikova,Tereza Hrnciarova,Roman Pawel Korolkiewicz,Marek Hraška,Jiřina Bartůňková,Radek Spisek

Dendritic cell vaccine (DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial.

2021

5521Background: Most patients with EOC relapse despite PDS and CMT. Autologous DCVAC can present tumor antigens to elicit a durable immune response. We hypothesized that adding DCVAC to CMT stimula...

Keywords:

Multicenter trial
Medicine
Internal medicine
Oncology
in patient
Antigen
Biomarker (medicine)
Chemotherapy
Epithelial ovarian carcinoma
Immune system
Debulking

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations